Oxford to lead trial of experimental drug in Ebola patients

13 November 2014

A clinical trial is to be carried out in West Africa to see whether a novel antiviral drug called brincidofovir is effective against Ebola, subject to regulatory approval.

The trial, involving an international team led by Oxford University scientists, will take place in an Ebola treatment centre run by Médecins Sans Frontières (MSF).

Ancient gene mutation found to cause rare hereditary condition

18 January 2021

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

18 January 2021

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Immunology preprint reviews launched in Nature Reviews Immunology

15 January 2021

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

14 January 2021

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

14 January 2021

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.

Oxford scientists: how we developed our COVID-19 vaccine in record time

13 January 2021